Metraipolis › archive › dc_715d88a080f0
Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer — Europe PMC PMID:28548467
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/28548467
- DOI
- 10.22034/apjcp.2017.18.4.1151
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T12:13:03.517Z
- SHA-256 of the archived text
eb46d622ce1d92107377bdfa3f1c587e7f66e27c458d7ade496483bb53e2e8bd- Stable URL of this page
https://metraipolis.com/documento/dc_715d88a080f0
How to cite
Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer — Europe PMC PMID:28548467 — Europe PMC (en), https://europepmc.org/article/MED/28548467 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_715d88a080f0 (Metraipolis archive dc_715d88a080f0, sha256 eb46d622ce1d92107377bdfa3f1c587e7f66e27c458d7ade496483bb53e2e8bd)
BibTeX
@misc{dc715d88a080f0,
title = {Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer — Europe PMC PMID:28548467},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/28548467},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_715d88a080f0; sha256 eb46d622ce1d92107377bdfa3f1c587e7f66e27c458d7ade496483bb53e2e8bd},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/28548467. Agents can read the archived copy with the MCP tool read_document.